Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication by G. Giugliano et al.
RESEARCH ARTICLE Open Access
Endovascular treatment of lower extremity
arteries is associated with an improved outcome
in diabetic patients affected by intermittent
claudication
Giuseppe Giugliano1, Cinzia Perrino1, Vittorio Schiano1, Linda Brevetti1, Anna Sannino1,
Gabriele Giacomo Schiattarella1, Giuseppe Gargiulo1, Federica Serino1, Marco Ferrone1, Fernando Scudiero1,
Andreina Carbone1, Antonio Bruno1, Bruno Amato2, Bruno Trimarco1, Giovanni Esposito1*
From XXV National Congress of the Italian Society of Geriatric Surgery
Padova, Italy. 10-11 May 2012
Abstract
Background: Lower extremity peripheral arterial disease (LE-PAD) is a highly prevalent condition among diabetic
patients, associated with reduced walking capacity and a high incidence of cardiovascular events. Endovascular
revascularization of lower extremities arteries improves walking performance and quality of life of diabetic patients
affected by intermittent claudication, but few studies evaluated the impact of revascularization on cardiovascular
outcome in this high-risk population. Accordingly, in the present study we evaluated if leg-ischemia resolution by
effective lower limbs percutaneous revascularization can also impact cardiovascular outcome in a homogeneous
group of diabetic patients affected by intermittent claudication.
Methods: 236 diabetic patients affected by LE-PAD at stage II of Fontaine’s classification, with ankle/brachial index
≤0.90 and one or more hemodynamically significant stenosis in at least one artery of the ileo-femoro-popliteal axis
were enrolled in the study. According to the Trans-Atlantic Inter Society Consensus II recommendations,
123 (52.1%) underwent percutaneous transluminal angioplasty (PTA group), while 113 (47.9%) underwent
conservative medical therapy only (MT group). The incidence of major cardiovascular events (cardiovascular death,
myocardial infarction, ischemic stroke, coronary or carotid revascularization) was prospectively analyzed with
Kaplan-Meier curves and the risk of developing a cardiovascular event calculated by Cox analyses.
Results: No baseline difference in cardiovascular risk factors were observed between the PTA and MT groups,
except for a lower prevalence of males in PTA group (74.8% vs. 85.8%, p=0.034). Furthermore, patients in the PTA
group showed a worse walking capacity as expressed by maximum walking distance (108.7 ± 300.9 vs 378.4 ±
552.3 meters, p<0.001). During a median follow-up of 20 months (12.0-29.0), the incidence of cardiovascular events
was markedly lower in patients in the PTA group with respect to patients in the MT group (7.3% vs. 22.1%,
p=0.001), and patients of the MT group had at Cox analysis a 3.9 increased risk with respect to PTA group, after
adjustment for potential confounding factors (95% CI 1.1-15.3, p=0.049).
Conclusions: The present study shows that lower limbs revascularization of diabetic patients affected by
intermittent claudication, in addition to improve walking performance, is associated with a reduction in the
incidence of future major cardiovascular events.
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Background
Cardiovascular disease (CVD) represents the leading
cause of death in western countries affecting especially
middle-age people [1-3]. One of the most important risk
factor, widely recognized as an independent predictor of
outcome, is diabetes [4,5]. Diabetes affects nearly all vas-
cular beds and in affected patients the risk of morbidity
is about twice that of age-matched non diabetic patients
[6]. The metabolic disorders accompanying diabetes
seem to accelerate the progression of atherosclerosis and
indeed more than half of diabetics will die as a result of a
cardiovascular ischemic event [7,8].
Lower extremity peripheral arterial disease (LE-PAD),
one of the main expressions of atherosclerosis, is a highly
prevalent pathological condition among diabetic patients
associated with reduced walking capacity and a high inci-
dence of developing future cardiovascular ischemic events
[9-14]. When LE-PAD develops in the setting of diabetes,
it portends a significantly increased danger to both life and
limb function [15,16].
While revascularization should be attempted without
delay in all patients presenting with critical limb ische-
mia, whenever technically possible, the management of
intermittent claudication varies depending on the sever-
ity of walking impairment and the associated impact of
this functional disability on individual lifestyle [17].
According to the most recent guidelines, LE-PAD
patients with limited walking capacity should be mana-
ged with limb revascularization procedures only when
exercise and/or drug therapy fail to improve symptoms
[17-23]. Both open repair/bypass surgery or percuta-
neous trans-luminal angioplasty (PTA) are effective
revascularization approaches, and the choice is based
upon the number, length and localization of the stenosis/
occlusion, surgery risk score and patient preference [3,18].
PTA of the lower limbs is effective in improving not only
functional status and quality of life in claudicants, [21,23]
but it is also associated with improved cardiovascular out-
come [9]. Whether these effects can be also observed in
patients with diabetes and intermittent claudication is cur-
rently unknown. Thus, we conducted a prospective study
to evaluate whether effective endovascular revasculariza-
tion by PTA might be associated with a reduction in cardi-
ovascular events compared to medical therapy only in a
homogeneous cohort of diabetic patients affected by
LE-PAD and intermittent claudication.
MethodsE
Study population
Consecutive diabetic patients referred to our vascular
laboratory for suspected intermittent claudication were
screened for enrollment in this study. Criteria for study
entry were all of the following: 1) diagnosis of diabetes
mellitus; 2) LE-PAD at stage II of Fontaine’s classification
(intermittent claudication); 2) ABI ≤0.90; 3) one or more
hemodynamically significant stenosis in at least one
artery of the ileo-femoro-popliteal axis at B-mode ultra-
sound. Exclusion criteria were: 1) critical limb ischemia;
2) previous lower limb revascularization; 3) recent acute
coronary or cerebrovascular ischemic events (6 months);
4) recent coronary or carotid revascularization proce-
dures (6 months); 5) abnormal myocardial ischemia
stress test at enrollment; 6) de-compensated heart failure;
7) malignant neoplasia or significant hepatic, renal, or
inflammatory disease.
According to the inclusion/exclusion criteria, 252 con-
secutive diabetic patients affected by intermittent claudi-
cation were selected. All patients were treated with
maximal medical therapy and encouraged to engage reg-
ular physical exercise for at least three months. After this
time, patients complaining a severe disability caused by
claudication, unable to perform normal work or with
very serious impairment of daily life activities despite
maximal medical therapy and regular physical exercise
(n=139) were selected for angiography and eventually
revascularization, while the remaining 113 patients were
managed with medical therapy only (MT group). Among
the patients initially selected for revascularization,
2 patients refused to undergo angiography, and were
excluded from the study. Based on the angiograms,
12 patients displaying TASC D lesions were excluded
from the study, while 125 underwent endovascular revas-
cularization. Following PTA, only 123 patients displayed
a successful angiographic result (2 patients showed a resi-
dual stenosis >30%), and therefore were included in
the study (PTA group). All participants gave written
informed consent to the study, which was approved by
our institutional ethics committee.
Clinical assessment
In each patient, clinical history and risk factors were
assessed at first visit. Smokers included current and for-
mer smokers. Hypertension was diagnosed if systolic
arterial pressure exceeded 140 mmHg and/or diastolic
arterial pressure exceeded 90 mmHg on repeated mea-
surements, or if the patient used antihypertensive drugs.
Hypercholesterolemia was diagnosed if plasma total cho-
lesterol exceeded 200 mg/dl, plasma low-density lipopro-
tein cholesterol exceeded 130 mg/dl, or if the patient
used lipid-lowering drugs because of a history of hyperch-
olesterolemia. Hospital records documented previous
cardiovascular events.
ABI and maximum walking distance assessment
ABI was measured at the first visit after participants had
rested supine for 5 minutes. The systolic blood pressure
in both brachial arteries and the ankle systolic blood
pressure for the right and left posterior tibial and dorsalis
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pedis arteries were measured using a Doppler probe. The
ABI for each leg was then determined using the higher of
the two readings from either the posterior tibial or dorsalis
pedis arteries, and the higher of the two brachial readings.
The lower ABI of the two legs was used for diagnostic
purposes and as predictor of future cardiovascular events.
Maximum walking distance (MWD) was tested by tread-
mill (speed 3 km/h, inclination 10%) at the first visit.
Endovascular procedure
Percutaneous Transluminal Angioplasty (PTA) was per-
formed after diagnostic angiography and intra-venous
injection of 70 U/kg of unfractionated heparin. Bailout
nitinol self-expanding stent implantation was performed
when a suboptimal angiographic result was obtained.
Successful angioplasty was defined by a final angiogram
with residual stenosis <30%.
Assessment of cardiovascular events
Patients underwent regular follow-up clinical examina-
tions at our Institution at 3-month intervals. The occur-
rence of cardiovascular death, myocardial infarction,
ischemic stroke and coronary or carotid revasculariza-
tions was prospectively assessed. Cardiovascular deaths
comprised fatal myocardial infarction, fatal stroke, sud-
den death, and death secondary to arrhythmia or refrac-
tory heart failure. The minimum follow-up period was
6 months. Medical records and death certificates of all
patients who had an event were obtained and validated
by a physician unaware of patient’s peripheral treatment.
For patients who had more than 1 event, only the first
was considered in the analysis.
Statistical analysis
Statistical analyses were performed using SPSS 16.0
(SPSS, Inc., Chicago, IL, USA). Variables were expressed
as absolute numbers and percentage or mean ± SD,
with the exception of leukocyte count that was
expressed as median and inter-quartile range because of
its skewed distribution. Comparisons were made by
t-test for unpaired samples, c2 test, or Mann-Whitney
U test, as appropriate. Cumulative event rates in the
PTA vs. MT group were estimated by Kaplan-Meier
curves and probability values by log-rank test.
Cox proportional hazard analyses were performed to
verify if endovascular treatment was associated with a
lower incidence of future cardiovascular events. The fol-
lowing covariates, known to be potential contributors of
cardiovascular risk, were included in the adjusted
model: age, sex, smoking, hypercholesterolemia, hyper-
tension, baseline ABI, baseline maximum walking dis-
tance, and leukocyte count.
All statistical tests were two-sided. For all tests, a
p-value < 0.05 was considered statistically significant.
Results
Patients’ characteristics
Table 1 reports the baseline characteristics of the patients
in the PTA and MT groups. There were fewer males in
the PTA group with respect to MT group (74.8% vs.
85.8%, p=0.034) and, not surprisingly, the MT group was
characterized by a better functional capacity (maximum
walking distance: 378.4 ± 552.3 vs. 108.7 ± 300.9 meters,
p<0.001). Conversely, no difference between the two
groups was observed with respect to the prevalence of
classic cardiovascular risk factors, cardiovascular co-
morbidity, and baseline ABI.
Endovascular treatment and outcome
During a median follow-up of 20.0 months (interquartile
range 12.0 – 29.0), 34 of the 236 patients (14.4%) had a
major cardiovascular event, of which 25 (22.1%) occurred
in the MT group, while only 9 (7.3%) occurred in the PTA
group (p<0.001). Importantly, the PTA group was charac-
terized by a lower rate of cardiovascular deaths, especially
driven by a reduction in the rate of fatal MI (data not
shown). Consistent with these results, Kaplan-Meier
curves depicting the incidence during follow-up of total
cardiovascular events showed a significant advantage in
the PTA group vs. MT group (Figure 1).
At Cox analysis, patients in the MT group had a 2.68-
fold increased risk (95% CI 1.24-5.74, p = 0.011) of
developing a cardiovascular event with respect to
patients in the PTA group. Notably, this association
remained statistically significant after adjustment for the
Table 1 Baseline characteristics of the study population
PTA Group MT Group p
(n = 123) (n = 113)
Age (yr) 64.7 ± 9.7 66.2 ± 8.9 0.323
Males 92 (74.8) 97 (85.8) 0.034
Risk factors
Hypercholesterolemia 98 (79.6) 79 (69.9) 0.152
Hypertension 112 (91.0) 183 (92.0) 0.757
Smoking 107 (87.0) 91 (80.5) 0.239
BMI 27.6 ± 5.3 26.5 ± 5.2 0.831
LE-PAD severity
ABI 0.66 ± 0.18 0.65 ± 0.17 0.580
MWD (meters) 108.7 ± 300.9 378.4 ± 552.3 0.001
Comorbidity
Previous MI 32 (26.0) 33 (29.2) 0.584
Previous stroke 3 (2.4) 1 (0.9) 0.360
Inflammatory status
Leukocyte count (x 109/L) 7.9 [6.6 – 9.3] 7.4 [5.9 – 9.1] 0.150
Values are n (%) or mean ± SD or median [interquartile range].
PTA = percutaneous transluminal angioplasty; MT = medical therapy; BMI = body
mass index; LE-PAD = lower extremity peripheral arterial disease; ABI = ankle/
brachial index; MWD = maximum walking distance; MI = myocardial infarction.
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potential confounders indicated above (adjusted HR=
3.92, 95% CI 1.10-15.30, p = 0.049).
Discussion
The present study demonstrates that successful revascu-
larization of lower extremity arteries in diabetic patients
affected by intermittent claudication is associated with a
reduction in the incidence of major cardiovascular
events. Notably, this association remains unaltered after
accounting for possible confounders such as classic cardi-
ovascular risk factors, previous myocardial infarction or
stroke, maximum walking distance, leukocyte count and
ABI, to date the most powerful prognostic indicator in
LE-PAD [24,25]. These results might have important
clinical implications, and might open a new scenario for
diabetic patients affected by intermittent claudication, in
which the indications to perform lower-extremity revas-
cularization might be extended to the improvement of
global cardiovascular outcome. At this regard, it is also
important to emphasize that PTA of the lower limbs is
now a safe and largely effective procedure [18,26].
Although patients undergoing PTA were characterized
by worse baseline functional capacity compared to the
MT group (Table 1), we observed a better cardiovascular
outcome in patients undergoing lower extremity reperfu-
sion strategy. Different mechanisms might be accounted
for these beneficial effects associated to the revasculariza-
tion of the ischemic leg. Firstly, PTA increases walking
capacity [20,22], and such improvement in functional sta-
tus induced by PTA might be responsible, at least in part,
of the reduction of cardiovascular risk observed in our
patients. Indeed, patients affected by intermittent claudi-
cation may be severely limited in their occupational and
leisure-time physical activity [27,28] and a sedentary life-
style is a risk factor for adverse cardiovascular events
[29-31]. Another possible mechanism for the favourable
effects observed in the PTA group might be inherent to
the increase of ABI. Indeed, successful revascularization
of lower extremities has been shown to improve the ABI,
which is the most powerful prognostic indicator in LE-
PAD patients [24,25]. Furthermore, PTA of the lower
limbs has been also associated with the improvement of
endothelial function [32], which plays an important role
in the pathophysiology and natural history of lower extre-
mities atherosclerotic disease [33], and may reduce the
ischemia–reperfusion injury which promotes systemic
inflammation [34]. At this regard, it is important to
emphasize that an increased inflammatory status has
been associated to the development and subsequent wor-
sening of atherosclerosis including thrombotic complica-
tions, and that the elevation in circulating inflammatory
markers increases the risk if ischemic cardiovascular
events in LE-PAD [13].
Conclusions
In conclusion, the present study provides evidence that
effective lower limb revascularization by PTA in diabetic
patients affected by intermittent claudication not only
ameliorates functional status and alleviates symptoms,
but is also associated with an improvement of cardiovas-
cular outcome. Further studies are needed to understand
the possible mechanisms underlying this result.
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